Synovial Sarcoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Advenchen Laboratories, Ipsen, Oncotherapy Science, C4 Therapeutics, Takara Bio, Bioatla

(MENAFN- GetNews)


"Synovial Sarcoma Clinical Trials"DelveInsight's,“Synovial Sarcoma- Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Synovial Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

According to DelveInsight, the Synovial Sarcoma pipeline includes over 15 major companies actively developing more than 20 therapeutic candidates for the treatment of Synovial Sarcoma.

Synovial Sarcoma Overview:

Synovial sarcoma is a rare type of soft tissue cancer that usually develops near joints or tendons, most frequently in the arms and legs, though it can arise in other locations as well. Despite its name, it does not originate from synovial tissue; instead, it is linked to a specific genetic alteration-a translocation between chromosomes X and 18 (t(X;18))-that drives abnormal tumor growth.

This cancer primarily affects adolescents and young adults between the ages of 15 and 40, with a slightly higher incidence in males. Synovial sarcoma often grows slowly, which can make early diagnosis challenging. Common symptoms include swelling, a noticeable mass near a joint, pain, and tenderness. In more advanced cases, the tumor may involve nearby muscles, nerves, or bones, resulting in joint dysfunction and limited mobility.

Request for a detailed insights report on Synovial Sarcoma pipeline insights

"Synovial Sarcoma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Synovial Sarcoma Therapeutics Market.

Key Takeaways from the Synovial Sarcoma Pipeline Report

• DelveInsight's Synovial Sarcoma pipeline report highlights a dynamic landscape, featuring over 15 active companies developing more than 20 therapeutic candidates for Synovial Sarcoma.

• Leading companies in this space-including Advenchen Laboratories, Ipsen, OncoTherapy Science, C4 Therapeutics, Takara Bio, BioAtla, Immatics Biotechnologies GmbH, Sapience Therapeutics, PharmaMar, and others-are investigating novel therapies aimed at improving treatment outcomes for patients. Notable pipeline candidates in various stages of development include OTSA101, Tazemetostat, AL3818, among others.

• Following the approval of Tecelra, Adaptimmune Therapeutics is exploring additional applications of its TCR technology. In February 2025, the FDA granted Breakthrough Therapy Designation to letetresgene autoleucel (lete-cel) for the treatment of myxoid/round cell liposarcoma (MRCLS), reflecting its potential to advance sarcoma therapies.

• Earlier, on August 2, 2024, the FDA granted accelerated approval to Tecelra (afamitresgene autoleucel) for adults with unresectable or metastatic synovial sarcoma who had previously received chemotherapy. Tecelra is notable as the first gene therapy approved for this patient group and the first engineered T-cell receptor (TCR) therapy authorized for a solid tumor.

Synovial Sarcoma Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Synovial Sarcoma Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Synovial Sarcoma treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Synovial Sarcoma market.

Download our free sample page report on Synovial Sarcoma pipeline insights

Synovial Sarcoma Emerging Drugs

• AL3818: Advenchen Laboratories

• Tazemetostat: Ipsen

• OTSA101: OncoTherapy Science

Synovial Sarcoma Companies

More than 15 leading companies are actively working on therapies for Synovial Sarcoma, with Advenchen Laboratories having a drug candidate currently in the most advanced stage of development, Phase III.

DelveInsight's report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Synovial Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Synovial Sarcoma Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Synovial Sarcoma Therapies and Key Companies: Synovial Sarcoma Clinical Trials and advancements

Synovial Sarcoma Pipeline Therapeutic Assessment

. Synovial Sarcoma Assessment by Product Type

. Synovial Sarcoma By Stage

. Synovial Sarcoma Assessment by Route of Administration

. Synovial Sarcoma Assessment by Molecule Type

Download Synovial Sarcoma Sample report to know in detail about the Synovial Sarcoma treatment market @ Synovial Sarcoma Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Synovial Sarcoma Current Treatment Patterns

4. Synovial Sarcoma - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Synovial Sarcoma Late-Stage Products (Phase-III)

7. Synovial Sarcoma Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Synovial Sarcoma Discontinued Products

13. Synovial Sarcoma Product Profiles

14. Synovial Sarcoma Key Companies

15. Synovial Sarcoma Key Products

16. Dormant and Discontinued Products

17. Synovial Sarcoma Unmet Needs

18. Synovial Sarcoma Future Perspectives

19. Synovial Sarcoma Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Synovial Sarcoma Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

MENAFN27082025003238003268ID1109985363